How therapeutic HIV vaccination changes T-cell responses
Multi-omic understanding of the transformed host T-cell response to HIV following therapeutic vaccination
This project looks at whether therapeutic HIV vaccines can create new, better-working T cells in people living with HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11391004 on NIH RePORTER |
What this research studies
If you join, researchers will collect blood and immune cells before and after a therapeutic HIV vaccine and run multiple lab tests that measure gene activity, cell metabolism, and T-cell receptors. They will track whether vaccination expands existing T cells or brings up new T-cell clones and will test how well those cells can multiply and respond. The team will compare immune and metabolic patterns to find which conditions lead to stronger, more functional T-cell responses. Findings will be used to guide vaccine design and strategies that could improve immune control of HIV.
Who could benefit from this research
Good fit: People living with HIV who are on stable antiretroviral therapy and willing to receive a therapeutic vaccine and provide blood and follow-up samples.
Not a fit: People without HIV or those with medical conditions that prevent vaccination or safe participation are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, the work could help design vaccines or strategies that expand new, more effective T cells to improve viral control in people with HIV.
How similar studies have performed: Previous therapeutic HIV vaccine trials have had limited success at controlling the virus, but detailed immune-monitoring and multi-omic approaches are increasingly showing which T-cell changes matter.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Hartigan-O'connor, Dennis J. — University of California at Davis
- Study coordinator: Hartigan-O'connor, Dennis J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.